Recombinant Hepatitis B Vaccine (Engerix-B®) A Review of its Immunogenicity and Protective Efficacy Against Hepatitis B

GM Keating, S Noble - Drugs, 2003 - Springer
Recombinant Hepatitis B Vaccine (Engerix-B®) | Drugs Skip to main content SpringerLink
Account Menu Find a journal Publish with us Track your research Search Cart 1.Home 2.Drugs …

[HTML][HTML] Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B

DS Chen - Journal of hepatology, 2009 - Elsevier
Hepatitis B virus infection is a global health problem. Worldwide, about 360 million people
are chronically infected with the virus. They continue to spread the virus to others and are …

Hepatitis B vaccine

E Mast, F Mahoney, M Kane, HS Margolis - Vaccines, 2008 - books.google.com
Infection with papillomaviruses (PVs) is universal among humans. Infection with human PV
(HPV) was regarded until about 20 years ago as benign and self-limiting, resulting in …

Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review

SF Schillie, TV Murphy - Vaccine, 2013 - Elsevier
INTRODUCTION: Hepatitis B vaccination starting at birth provides a safety net for infants
exposed to hepatitis B virus (HBV) during delivery or in early life. Hepatitis B vaccine is …

Hepatitis B vaccine and the need for a booster dose after primary vaccination

C Pileggi, R Papadopoli, A Bianco, M Pavia - Vaccine, 2017 - Elsevier
Objectives Protective antibodies levels, induced by Hepatitis B virus (HBV) vaccine, persist
for long-term after primary immunization, but there is evidence that, as the time since …

Hepatitis B: immunization and impact on natural history and cancer incidence

CL Lin, JH Kao - Gastroenterology Clinics, 2020 - gastro.theclinics.com
As a global health problem, there are more than 2 billion people infected with hepatitis B
virus (HBV) worldwide. It is estimated that as many as 257 million of them have chronic HBV …

Active immunization of premature and low birth-weight infants: a review of immunogenicity, efficacy, and tolerability

CT D'Angio - Pediatric Drugs, 2007 - Springer
Preterm infants are at increased risk of disease and hospitalization from a number of vaccine-
preventable diseases. However, these same infants have immunologic immaturities that …

The immunogenicity of GSK's recombinant hepatitis B vaccine in children: a systematic review of 30 years of experience

C van den Ende, C Marano, A van Ahee… - Expert review of …, 2017 - Taylor & Francis
ABSTRACT Introduction: The World Health Organization recommends hepatitis B virus
(HBV) vaccines to be included in national immunization schedules everywhere, and has …

Vaccinations in the newborn

T Chaudhari - Best Practice & Research Clinical Obstetrics & …, 2021 - Elsevier
Neonatal immunisation includes vaccination in the first 4 weeks of life (Neonatal period) as
well as in high-risk preterm infants in the first few months (until 44 weeks corrected …

A retrospective study of hepatitis B vaccination in preterm birth and low birth weight infants born to hepatitis B surface antigen-positive mothers: Time to close the …

W Qin, Y Wang, X Zhang, F Pan, K Cheng… - Human Vaccines & …, 2022 - Taylor & Francis
ABSTRACT National Immunization Program-version 2016 (ISIV-NIP-v2016) recommended
a 4-dose hepatitis B vaccine (HepB) schedule for preterm birth (PTB) and low birth weight …